Covaxin 77.8% Effective In Phase 3 Trial Data: Sources
Bharat Biotech's Covaxin is 77.8 per cent effective in protecting against COVID-19, according to data from Phase III trials conducted on 25,800 participants across India. Sources said trial data and results were studied and recommended for approval by the DCGI's Subject Expert Committee on Tuesday. The data was submitted to the DCGI over the weekend.
Advertisement
